## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re appl	lication of:	Jill Giles-Kor	Jill Giles-Komar					
Application No.: Filed:		to be assigned November 24	i , 2003	Group No.: Examiner:				
For: ANTI-DUAL IN USES.			TEGRIN ANTIBODIES, COMPOSITIONS, METHODS AND					
P. O. Box	t Commission k 1450 ria, VA 22313							
SUBM AD	MENDMENT	PERTAINING THERI	ETO FOR B	TTER READABLE COPY, AND/OR SIOTECHNOLOGY INVENTION MINO ACID SEQUENCE.				
1. [	This replies to the Office Letter dated  A copy of the office letter is enclosed.							
	CERTIFICATION UNDER 37 C.F.R. §§ 1.8 (a) and 1.10* (When using Express Mail, the Express Mail label number is mandatory;  Express Mail certification is optional)							
I	I hereby certify that, on the date shown below, this correspondence is being:							
,	MAILING							
_	Patents, Wash 37 C.F.	the United States Postal Servicington, D.C. 20231 R. § 1.8(a) postage as first class mail.	ostal Service in an envelope addressed to the Assistant Commissioner for  37 C.F.R. § 1.10*  Is mail.  Is as "Express Mail Post Office to Addressee"  Mailing Label No. EU735850608US					
	TRANSMISSION							
[	transmitted by	facsimile to the Patent and Tra	demark Office. Signature	lemb for				
[	Date: 1//a	1/03	Kenneth (type or p	I. Dow rint name of person certifying)				
*	*WARNING: Each paper or fee filed by Express Mail must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. § 1.10(b).  "Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition. "Notice of October 24, 1996, 60 Fed. Reg. 56, 439, at 56.442.							

## IDENTIFICATION OF PERSON MAKING STATEMENT

2. I, Kenneth J. Dow\_\_\_state the following:

			ITEMS BEING SUBMITTED						
3.	Subm	itted	herewith is/are:						
	(check each item as applicable)								
	A.		*Sequence Listing(s)* for the nucleotide and/or amino acid sequence(s) in this application. Each *Sequence Listing* is assigned a separate identifier as required in 37 C.F.R. § 1.822 and 1.823.						
	В.		an amendment to the description and/or claims, wherein reference is made to the sequence by se of the assigned identifier, as required in 37 C.F. R. § 1.821(d).						
	C.	×	copy of each "Sequence Listing" submitted for this application in computer readable form, in coordance with the requirements of 37 C.F.R. §§ 1.824.						
	D.		Please transfer to this application, in accordance with 37 C.F.R. § 1.821(e), the computer readable copy (ies) from applicant's other application identified as follows:						
			In re application of:						
			Application No.: Group No.: Examiner: For:						
	E.	$\boxtimes$	A statement that the content of each "Sequence Listing" submitted and each computer readable Copy is the same, as required in 37 C.F.R. § 1.821(b).  Because the statement is not made by a person registered to practice before the Office, the statement is verified as required in 37 C.F.R. § 1.821(b).						
	F.	Because the submission is made in fulfilling the requirement under 37 C.F.R. § 1.821(g), a statement that the submission includes no new matter.  Because the statement is not made by a person registered to practice before the Office, the statement is verified, as required in 37 C.F.R. § 1.821(g).							
STATEMENT THAT "SEQUENCE LISTING" AND COMPUTER READABLE COPY ARE THE SAME AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER-									
4. I hereby state:									
	A.	⊠	(complete applicable item A and/or B) Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.						
	B.	Ø	All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.						

5. The proceedings herein are for a	5. The proceedings herein are for a patent application and the provisions of 37 C.F.R. § 1.136 apply.							
(complete (a) or (b) as applicable)								
(a) Applicant petitions for an extension of time under 37 C.F.R. § 1.136 (fees: 37 C.F.R. § 1.136 (fees: 1.17(a)(1)-(4) for the total number of months checked below:								
Extension (months)	Fee for other than small entity	Fee for small entity						
one month two months three months four months	\$ 110.00 \$ 400.00 \$ 920.00 \$ 1,440.00	\$ 55.00 \$ 200.00 \$ 460.00 \$ 720.00						
	Fee:	\$						
If an additional extension of time is required, please consider this a petition therefor.								
(check and complete the next item, if applicable)								
An extension formonths has already been secured. The fee paid therefor of \$is deducted from the total fee due for the total months of extension now requested.								
	Extension fee due w	with this request \$						
	OR							
(b) Applicant believes that no extension of term is required. However, this condition petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition for extension of time.								
	FEE PAYMEN	п						
8. Attached is a check money order in the amount of \$ Authorization is hereby made to charge the amount of \$ to Deposit Account No. 100750/CEN5249CIPNP/KD To Credit card as shown on the attached credit card information authorization form PTO-2038.								
Charge any additional fees required by this paper or credit any overpayment in the manner authorized above. A duplicate of this paper is attached.								
FEE DEFICIENCY								
9. ☑ If any additional extension and/or fee is required, charge ☐ Deposit Account No. 10-0750/CEN249CIPNP/KD. ☐ Credit card as shown on the attached credit card information authorization form PTO-2038.								
		SIGNATURE OF PRACTITIONER						
Reg. No.: 32,890		(type or print name of practitioner)						
Telephone No.: ( 610) 651-7422 Address Johnson & Johnson c/o Centocor, Inc. 145 King of Prussia Road Radnor, PA 19087 Telephone No. 610-651-7422 Customer No.: 000027777		Kenneth J. Dow						